

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT3818236

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
CENTREXION I, INC.	07/27/2015
RECEIVING PARTY DATA	
Name:	CENTREXION THERAPEUTICS CORPORATION
Street Address:	509 SOUTH EXETER STREET
Internal Address:	SUITE 202
City:	BALTIMORE
State/Country:	MARYLAND
Postal Code:	21202
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	11499989
CORRESPONDENCE DATA	
Fax Number:	(617)523-1231
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	617-570-1000
Email:	cedavis@goodwinprocter.com, jlegere@goodwinprocter.com, PatentBos@goodwinprocter.com
Correspondent Name:	GOODWIN PROCTER LLP
Address Line 1:	53 STATE STREET
Address Line 4:	BOSTON, MASSACHUSETTS 02109
ATTORNEY DOCKET NUMBER:	CNX-005D1
NAME OF SUBMITTER:	CHAD E. DAVIS
SIGNATURE:	/CHAD E. DAVIS/
DATE SIGNED:	04/06/2016
Total Attachments: 7	
source=CNX-005D1AssignmentCentrexionItoCentrexionCorporation#page1.tif	
source=CNX-005D1AssignmentCentrexionItoCentrexionCorporation#page2.tif	
source=CNX-005D1AssignmentCentrexionItoCentrexionCorporation#page3.tif	
source=CNX-005D1AssignmentCentrexionItoCentrexionCorporation#page4.tif	

source=CNX-005D1AssignmentCentrexionItoCentrexionCorporation#page5.tif

source=CNX-005D1AssignmentCentrexionItoCentrexionCorporation#page6.tif

source=CNX-005D1AssignmentCentrexionItoCentrexionCorporation#page7.tif

PATENT

REEL: 038207 FRAME: 0748

INTELLECTUAL PROPERTY RIGHTS ASSIGNMENT

This Intellectual Property Rights Assignment is made by and entered into as of July 28, 2015 by and between Centrexion I, Inc., a Delaware corporation having a principal place of business at 509 South Exeter Street, Suite 202, Baltimore, Maryland 21202 (hereinafter “ASSIGNOR”) and Centrexion Therapeutics Corporation, a Delaware corporation having a principal place of business at 509 South Exeter Street, Suite 202, Baltimore, Maryland 21202 (hereinafter “ASSIGNEE”).

WHEREAS, ASSIGNOR is a wholly-owned subsidiary of ASSIGNEE, and this Intellectual Property Rights Assignment is made pursuant to the Agreement and Plan of Merger between said ASSIGNOR and ASSIGNEE;

WHEREAS, ASSIGNOR holds all right title and interest in and to certain intellectual property including, but not limited to, inventions, copyrights, patents, and patent applications, such as the patents and patent applications identified in the attached Schedule A (hereinafter “Patent Rights”); collectively the “Intellectual Property Rights”;

WHEREAS, pursuant to the Agreement and Plan of Merger, ASSIGNOR has agreed to sell, assign, convey, and transfer to ASSIGNEE all of ASSIGNOR’S right, title and interest in, to and under the Intellectual Property Rights; and ASSIGNEE desires to receive the Intellectual Property Rights from ASSIGNOR.

NOW, THEREFORE, in consideration of the premises set forth above and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged:

ASSIGNOR does hereby sell, assign, convey, and transfer unto said ASSIGNEE, its successors, assigns, and legal representatives, ASSIGNOR’S entire right, title and interest in and throughout the United States of America, its territories and all foreign countries, in and to the Intellectual Property Rights, which for clarity, includes the invention(s) described and/or claimed in said Patent Rights, together with ASSIGNOR’S entire right, title and interest in and to the patents and patent applications listed in Schedule A and any patents that may issue thereon or any patents or patent applications that claim priority under United States law or international convention, including but not limited to non-provisionals, continuations, divisionals, reissues,

reexaminations, extensions, and substitutions of said patents and patent applications or such other patents, and any right, title and interest ASSIGNOR may have in applications to which said Patent Rights claim priority; said invention(s), patent applications and patents to be held and enjoyed by said ASSIGNEE for its own use and behalf and for its successors, assigns and legal representatives, to the full end of the term for which said patents may be granted as fully and entirely as the same would have been held by ASSIGNOR had this assignment and sale not been made; ASSIGNOR hereby conveys all of its rights arising under or pursuant to any and all United States laws and international agreements, treaties or laws relating to the protection of industrial property by filing any such applications for patent, including but not limited to any cause(s) of action and damages accruing prior to this assignment. ASSIGNOR hereby acknowledges that this assignment, being of ASSIGNOR's entire right, title and interest in and to said invention(s), applications and patents carries with it the right in ASSIGNEE to apply for and obtain from competent authorities in all countries of the world any and all patents by attorneys and agents of ASSIGNEE's selection and the right to procure the grant of all patents to ASSIGNEE in its own name as assignee of ASSIGNOR's entire right, title and interest therein;

AND, ASSIGNOR hereby further agrees for itself and its successors, assigns, agents, and legal representatives to execute upon request any other lawful documents and likewise to perform any other lawful acts which may be deemed necessary to secure fully the aforesaid Patent Rights to said ASSIGNEE, its successors, assigns, and legal representatives, as well as to third parties at the request of ASSIGNEE including the execution of non-provisional, substitution, continuation, divisional, reissue, reexamination, or corresponding foreign or international patent applications, and generally do everything possible to aid ASSIGNEE, its successors, assigns and legal representatives to obtain, record, maintain, and enforce full protection for the inventions in all countries, but in each instance at ASSIGNEE's reasonable expense;

AND, ASSIGNOR does hereby authorize and request the Director of the United States Patent and Trademark Office and the empowered officials of all other governments to issue such Patent Rights or patents as shall be granted upon said Patent Rights, or applications based thereon, to said ASSIGNEE, its successors, assigns, or legal representatives;

AND, ASSIGNOR hereby grants the following individuals the power to insert on this Assignment any further identification which may be necessary or desirable in order to

comply with the rules of the United States Patent and Trademark Office for recordation of this document:

GOODWIN PROCTER LLP

All practitioners at Customer Number 051414

[Remainder of page intentionally left blank]

IN WITNESS WHEREOF, ASSIGNOR and ASSIGNEE have caused this Assignment to be executed as a sealed instrument by their duly authorized representatives as of the date first written above.

ASSIGNOR:

Name: CENTREXION, I, INC.
Signature: [Signature]
Title: _____
Date: _____

On this 27th day of July, 2015, before me, the undersigned Notary Public, personally appeared Jeffrey Knudler, proved to me through satisfactory evidence of identification, which was/were driver's license, to be the person whose name is signed on the preceding or attached document, and who swore or affirmed to me that the contents of the document are truthful and accurate to the best of his/her knowledge and belief. The above-indicated individual is duly authorized to execute this document singly on behalf of Assignor and executed this document of his/her own free will.

[Signature]
Signature of Notary

My Commission Expires: 10/22/2017

(Seal)

DANIEL A. LANG
Notary Public, State of New York
No. 02LA6270651
Qualified in New York County
Commission Expires October 22, 2017

ASSIGNEE:

Name: CENTREXION
THERAPEUTICS
CORPORATION
Signature: [Signature]
Title: _____
Date: _____

On this 27th day of July, 2015, before me, the undersigned Notary Public, personally appeared Jeffrey Knudler, proved to me through satisfactory evidence of identification, which was/were driver's license, to be the person whose name is signed on the preceding or attached document, and who swore or affirmed to me that the contents of the document are truthful and accurate to the best of his/her knowledge and belief. The above-indicated individual is duly authorized to execute this document singly on behalf of Assignor and executed this document of his/her own free will.

[Signature]
Signature of Notary

My Commission Expires: 10/22/2017

(Seal)

DANIEL A. LANG
Notary Public, State of New York
No. 02LA6270651
Qualified in New York County
Commission Expires October 22, 2017

[SIGNATURE PAGE TO INTELLECTUAL PROPERTY RIGHTS ASSIGNMENT]

SCHEDULE A

Docket No.	Country	Application Serial No. / Publication No.	Date Filed	Patent No.
ATI 100	U.S.	12/192,871	Aug. 15, 2008	
ATI 100/US CON	U.S.	14/483,839	Sept. 11, 2014	
ATI 100 PCT	PCT	PCT/US2008/073381	Aug. 15, 2008	
ATI 100 AU	Australia	2008289109	Aug. 15, 2008	2008289109
ATI 100 CA	Canada	2,696,632	Aug. 15, 2008	2,696,632
ATI 100 EP	Europe	08798025.6	Aug. 15, 2008	
ATI 100 HK	Hong Kong	10109691.1	Oct. 13, 2010	
ATI 100 JP	Japan	2010-521214	Aug. 15, 2008	5358574
ATI 101	US	12/542,365	Aug. 17, 2009	8,119,694
ATI 101 CON	US	13/401,088	Feb. 21, 2012	
VAL 1007	US	60/461,164	04/08/2003	
VAL 1007	US	60/434,530	12/18/2002	
VAL 1007	US	60/434,501	12/18/2002	
VAL 1007	US	60/434,500	12/18/2002	
VAL 1007	US	60/434,453	12/18/2002	
VAL 1007	US	60/434,452	12/18/2002	
VAL 1007	US	60/434,828	12/18/2002	
VAL 1004	US	10/742,441	12/18/2003	
VAL 1004 CON	US	12/287,746	10/14/2008	
VAL 1007	US	10/742,621	12/18/2003	
VAL 1007 DIV	US	11/499,995	08/07/2006	8,420,600
VAL 1007 CON	US	12/077,494	03/18/2008	
VAL 1007 DIV/CON	US	13/862,260	04/12/2013	
VAL 1007	PCT	PCT/US03/40356	12/18/2003	
VAL 1007	AR	P05-01-02460	12/18/2003	
VAL 1007	AU	2003299691	12/18/2003	2003299691
VAL 1007	BR	PI-0316906-5	12/18/2003	
VAL 1007	CA	2510181	12/18/2003	2510181
VAL 1007	CN	200380109828.0	12/18/2003	ZL20038010 9828.0
VAL 1007 DIV	CN	200910164452.2	12/18/2003	
VAL 1007	EA	200500986	12/18/2003	EA011708
VAL 1007	EP	03799973.7	12/18/2003	
VAL 1007	HK	12103200.6	12/18/2003	
VAL 1007	IL	169214	12/18/2003	
VAL 1007	IN	2648/DELNP/2005	12/18/2003	
VAL 1007 DIV	IN	8523/DELNP/2008	10/10/2008	
VAL 1007	JP	2005-510006	12/18/2003	
VAL 1007 DIV	JP	2010-156675	12/18/2003	
VAL 1007 DIV	JP	2013-213382	12/18/2003	
VAL 1007	MX	006670	12/18/2003	
VAL 1007	NZ	540769	12/18/2003	540769
VAL 1007 DIV	NZ	574630	02/02/2009	
--	US	60/531,074	12/18/2003	
VAL 1009	US	10/821,473	04/08/2004	
VAL 1009 DIV	US	11/880,990	07/25/2007	

Docket No.	Country	Application Serial No. / Publication No.	Date Filed	Patent No.
VAL 1009	PCT	PCT/US04/10745	04/08/2004	
VAL 1009	AR	P05-01-04230	04/08/2004	
VAL 1009	AU	2004230915	04/08/2004	2007230915
VAL 1009	BR	2004PI09748	04/08/2004	
VAL 1009	CA	2521925	04/08/2004	
VAL 1009	CN	200480015966.7	04/08/2004	100500142
VAL 1009	EA	200501582	04/08/2004	
VAL 1009	EP	04749854.8	04/08/2004	
VAL 1009	IL	171282	04/08/2004	
VAL 1009	IN	National phase of PCT/US04/10745	04/08/2004	
VAL 1009	JP	20060509790	04/08/2004	
VAL 1009	MX	MX2005PA10882	04/08/2004	
VAL 1009	NZ	542887	04/08/2004	542887
VAL 1009	AM	200501582	04/08/2004	
VAL 1009	AZ	200501582	04/08/2004	
VAL 1009	BY	200501582	04/08/2004	
VAL 1009	KG	200501582	04/08/2004	
VAL 1009	KZ	200501582	04/08/2004	
VAL 1009	MD	200501582	04/08/2004	
VAL 1009	RU	200501582	04/08/2004	
VAL 1009	TJ	200501582	04/08/2004	
VAL 1009	TM	200501582	04/08/2004	
VAL 1013	US	10/741,197	12/18/2003	
VAL 1013 CON	US	12/288,019	10/16/2008	
VAL 1014	US	10/741,196	12/18/2003	
VAL 1014 CON	US	12/288,033	10/16/2008	
VAL 1019	US	10/741,194	12/18/2003	
VAL 1019 CON	US	12/288,020	10/16/2008	
VAL 1020	US	10/742,443	12/18/2003	
VAL 1020 CON	US	12/228,226	08/11/2008	
VAL 1027	PCT	PCT/US03/40766	12/18/2003	
VAL 1027	AU	0301190	12/18/2003	
VAL 1027	AT	0813821	12/18/2003	AT401874
VAL 1027	DK	0813821	12/18/2003	DK1587506
VAL 1027	EP	03813821.0	12/18/2003	EP1587506
VAL 1027	ES	030813821	12/18/2003	ES2311756
VAL 1027	JP	2005-502659	12/18/2003	
VAL 1027	PT	0813821T	12/18/2003	PT1587506
VAL 1027	SI	20030031389	12/18/2003	SI1587506
VAL 1027	BG	0813821	12/18/2003	
VAL 1027	CH	0813821	12/18/2003	
VAL 1027	CY	0813821	12/18/2003	
VAL 1027	CZ	0813821	12/18/2003	
VAL 1027	DE	0813821	12/18/2003	60322436
VAL 1027	FI	0813821	12/18/2003	
VAL 1027	FR	0813821	12/18/2003	
VAL 1027	GR	0813821	12/18/2003	
VAL 1027	HU	0813821	12/18/2003	
VAL 1027	IE	0813821	12/18/2003	
VAL 1027	IT	0813821	12/18/2003	

Docket No.	Country	Application Serial No. / Publication No.	Date Filed	Patent No.
VAL 1027	LU	0813821	12/18/2003	
VAL 1027	MC	0813821	12/18/2003	
VAL 1027	NL	0813821	12/18/2003	
VAL 1027	RO	0813821	12/18/2003	
VAL 1027	SE	0813821	12/18/2003	
VAL 1027	SK	0813821	12/18/2003	
VAL 1027	UK	0813821	12/18/2003	
VAL 1028	US	10/741,195	12/18/2003	
VAL 1028 DIV	US	11/499,989	08/07/2006	8,367,733
VAL 1028 CON(2)	US	12/077,492	03/18/2008	
--	US	60/630,577	11/24/2004	
VAL 1034	US	11/286,059	11/23/2005	
VAL 1034	PCT	PCT/US05/42578	11/23/2005	
VAL 1034	AR	National phase of PCT/US05/42578	11/23/2005	
VAL 1034	AU	2005309586	11/23/2005	
VAL 1034	BR	PI0516912	11/23/2005	
VAL 1034	CA	2596194	11/23/2005	
VAL 1034	CN	2005800471	11/23/2005	
VAL 1034	EA	20070001131	11/23/2005	
VAL 1034	EP	5853319.1	11/23/2005	
VAL 1034	IL	183332	11/23/2005	
VAL 1034	IN	3852/DELNP/2007	11/23/2005	
VAL 1034	JP	2007543484	11/23/2005	
VAL 1034	MX	MX20070006253	11/23/2005	
VAL 1034	NZ	555331	11/23/2005	
VAL 1035	US	61/136,545	09/12/2008	
VAL 1035	US	12/559,071	09/14/2009	8,158,682
VAL 1035	PCT	PCT/US08/10706	09/12/2008	
--	US	61/193,790	12/23/2008	
--	US	61/180,263	05/21/2009	
CNX-009PR	US	62/030,298	07/29/2014	